Ramon R Marquez, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 6911 Tara Blvd # A, Jonesboro, GA 30236 Phone: 770-477-8573 Fax: 770-477-9045 |
Dr. Abelardo B Magat, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 6911 Tara Blvd # A, Jonesboro, GA 30236 Phone: 770-477-8573 Fax: 770-477-9045 |
Rajiv Sood, D.O. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1287 Georgia Highway 138 Spur Road, Suite #8, Jonesboro, GA 30236 Phone: 770-473-0038 Fax: 770-471-4290 |
Dr. Lovelina M Sood, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 1287 Highway 138 Spur, Suite 8, Jonesboro, GA 30236 Phone: 770-471-9990 Fax: 770-471-4290 |
News Archive
When transplant clinics must publicly report their success rates, this should provide an incentive to improve care for patients. But a recent study appearing in the Clinical Journal of the American Society Nephrology (CJASN) found that such public reporting has not had any effect on the care that transplant patients receive.
A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus - a bacterial infection that causes pneumonia, meningitis and sepsis - are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death.
Biovail Corporation today announced that the Company's Board of Directors has declared a quarterly cash dividend of US$0.09 per share payable on April 5, 2010 to shareholders of record at the close of business March 8, 2010. The ex-dividend date is March 4, 2010.
The heart of modern therapy is increasingly personalized and targeted at specific cellular or genetic deficits. This requires gene therapy, in many cases. A new study, published on 19 September 2019 in the journal Nature, describes an improved way to produce purified gene carrier viruses called AAVs cheaply and quickly, from the culture medium.
A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 2 days ago